Showing 7731-7740 of 8649 results for "".
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be
- Oxurion to Present New Preclinical Data on THR-687 at EURETINA 2020 Virtual Meetinghttps://modernod.com/news/oxurion-to-present-new-preclinical-data-on-thr-687-at-euretina-2020-virtual-meeting/2478342/Oxurion NV announced that it will present new preclinical data on THR-687 at the European Society of Retina Specialists (EURETINA) 2020 Virtual Meeting taking place October 2-4. The company will make two presentations on preclinical data at the meeting as follows (sessions are virtual so h
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- Novavax Begins Phase 3 Coronavirus Vaccine Trial in UKhttps://modernod.com/news/novavax-begins-phase-3-coronavirus-vaccine-trial-in-uk/2478330/Novavax said Thursday it has initiated its first phase 3 study to evaluate the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate NVX-CoV2373. The trial, which is being conducted in the UK, is expected to enroll up to 10,000 individuals between the ages of 18 and 84 years, with
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- Trump Signs Executive Orders on Preexisting Condition Protections, Surprise Billinghttps://modernod.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/President Donald Trump signed an executive order that declares it a national policy to protect patients with preexisting conditions regardless of the fate of the Affordable Care Act (ACA)—but just how they’ll force insurers to comply remains unclear, according to a FierceHealthcare
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp
- UK to Run Challenge Trials for COVID-19 Vaccines: Reporthttps://modernod.com/news/uk-to-run-challenge-trials-for-covid-19-vaccines-report/2478317/The UK government will fund challenge trials that are expected to begin in January to assess the effectiveness of experimental coronavirus vaccines, the Financial Times reported Wednesday, citing people familiar with the project. According to the report, researchers said the
- Whitney Hauser, OD, FAAO, Joins Novartis Ophthalmicshttps://modernod.com/news/whitney-hauser-od-faao-joins-novartis-ophthalmics/2478318/Novartis has announced that Whitney Hauser, OD, FAAO, will be joining the team as Director, Peer Education for US Ophthalmics. In this capacity, Dr. Hauser will bring her experience as a professor, clinician and founder of the Dry Eye Coach to help shape Novartis’ education and engagement